Fig. 3: Jawsamycin does not display activity against the human SPT14 homolog PIG-A. | Nature Communications

Fig. 3: Jawsamycin does not display activity against the human SPT14 homolog PIG-A.

From: Jawsamycin exhibits in vivo antifungal properties by inhibiting Spt14/Gpi3-mediated biosynthesis of glycosylphosphatidylinositol

Fig. 3

a Cytotoxicity assessment by dose-response testing of jawsamycin and the control compound benzalkonium chloride against human HCT116 cells. b Genetic validation of the FLAER assay: genetic editing of the PIG-A gene leads to loss of extracellular concentration of GPI-anchored proteins in HCT116 cells as assessed by staining with the fluorescently labeled GPI-binding compound aerolysin (FLAER) and flow-cytometry analysis. c Incubation of HCT116 cells with different doses of jawsamycin has no apparent effect on GPI-anchored proteins as observed by FLAER staining and flow-cytometry analysis. For each histogram in panel a and b, 10,000 events were recorded and peak heights normalized. Unstained and untreated control samples were used to set the gating strategy (gating strategy images and additional data are provided in the Source Data file).

Back to article page